Objective: Tenofovir Disoproxil Fumarate (TDF) is effective in treating Hepatitis B Virus (HBV) but has been associated with nephrotoxicity. In contrast, Tenofovir Alafenamide Fumarate (TAF) has emerged as a safer alternative, reducing kidney exposure while maintaining antiviral efficacy. This meta-analysis evaluates improvements in kidney function following the switch from TDF to TAF. Methods: Our study was registered in PROSPERO (CRD42024565358) and included 10 randomized controlled trials (RCTs) involving 1,179 patients with Chronic Kidney Disease (CKD). We compared renal function before and after switching to TAF Results: Significant improvements in glomerular filtration rate (GFR) were observed, indicating enhanced kidney function post-switch. The findings confirm that TAF demonstrates a superior renal safety profile compared to TDF, particularly in long-term treatments. Conclusion: The clinical relevance of TAF for HBV patients with CKD aligns with current guideline shifts favoring TAF. Despite limitations such as high heterogeneity, this study supports TAF as a safer management strategy for HBV patients with CKD, demonstrating improved kidney outcomes and reduced nephrotoxicity risks. These findings support its broader use in clinical practice and highlight the need for further research on long-term renal outcomes.

Introduction: Tenofovir disoproxil fumarate (TDF) is effective in treating hepatitis B virus, (HBV) but has been associated with nephrotoxicity. In contrast, tenofovir alafenamide fumarate (TAF) has emerged as a safer alternative, reducing kidney exposure while maintaining antiviral efficacy. This meta-analysis evaluates improvements in kidney function following the switch from TDF to TAF. Methods: Our study was registered in PROSPERO (CRD42024565358) and included 10 randomized controlled trials (RCTs) involving 1,179 patients with chronic kidney disease (CKD). We compared renal function before and after switching to TAF. Results: Significant improvements in glomerular filtration rate (GFR) were observed, indicating enhanced kidney function post-switch. The findings confirm that TAF has a superior renal safety profile compared to TDF, particularly in long-term treatments. Conclusion: The clinical relevance of TAF for HBV patients with CKD aligns with current guideline shifts favoring TAF. Despite limitations such as high heterogeneity, this study supports TAF as a safer management strategy for HBV patients with CKD, demonstrating improved kidney outcomes and reduced nephrotoxicity risks. These findings support its broader use in clinical practice and highlight the need for further research on long-term renal outcomes.

Human immunodeficiency virus (HIV) depletes CD4+ lymphocytes, compromising cellular immunity and increasing susceptibility to opportunistic infections. Additionally, HIV can lead to neurocognitive, motor, and sensory impairments known as HIV-associated neurocognitive disorders (HAND), which encompass symptoms ranging from concentration difficulties and psychomotor slowing to depressive states, irritability, and, in advanced stages, dementia. Cholinesterase inhibitors, commonly used in Alzheimer's disease, are a potential therapeutic option for cognitive decline in HAND. An integrative literature review was conducted using PubMed, Embase, and the Cochrane Library databases to identify relevant studies on the use of cholinesterase inhibitors in individuals diagnosed with HAND. The literature search yielded studies that explore the efficacy and safety of cholinesterase inhibitors in HAND, highlighting both potential cognitive benefits and the need for further evidence. However, findings remain limited and inconclusive regarding robust clinical recommendations. While cholinesterase inhibitors represent a promising therapeutic approach for HAND-related cognitive decline, current evidence is insufficient to support widespread clinical use. Further controlled studies are necessary to establish their efficacy and safety in this specific population.

Anais do Congresso Brasileiro Interdisciplinar em Ciência e Tecnologia (2764-0582) - Biocirculation: Um Jogo Estratégico Para O Ensino Da Biofísica Da Circulação